These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38436963)

  • 1. Dementia Prevention and Treatment: A Narrative Review.
    Reuben DB; Kremen S; Maust DT
    JAMA Intern Med; 2024 May; 184(5):563-572. PubMed ID: 38436963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
    Burns A; O'Brien J; ; Auriacombe S; Ballard C; Broich K; Bullock R; Feldman H; Ford G; Knapp M; McCaddon A; Iliffe S; Jacova C; Jones R; Lennon S; McKeith I; Orgogozo JM; Purandare N; Richardson M; Ritchie C; Thomas A; Warner J; Wilcock G; Wilkinson D;
    J Psychopharmacol; 2006 Nov; 20(6):732-55. PubMed ID: 17060346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
    Buckley JS; Salpeter SR
    Drugs Aging; 2015 Jun; 32(6):453-67. PubMed ID: 25941104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Burns A;
    J Psychopharmacol; 2011 Aug; 25(8):997-1019. PubMed ID: 21088041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Management of Dementia: Review.
    Arvanitakis Z; Shah RC; Bennett DA
    JAMA; 2019 Oct; 322(16):1589-1599. PubMed ID: 31638686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of cognitive impairment.
    von Arnim CAF; Bartsch T; Jacobs AH; Holbrook J; Bergmann P; Zieschang T; Polidori MC; Dodel R
    Z Gerontol Geriatr; 2019 Jul; 52(4):309-315. PubMed ID: 31161337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
    Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
    Desmidt T; Hommet C; Camus V
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Alzheimer disease.
    Winslow BT; Onysko MK; Stob CM; Hazlewood KA
    Am Fam Physician; 2011 Jun; 83(12):1403-12. PubMed ID: 21671540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force.
    Lin JS; O'Connor E; Rossom RC; Perdue LA; Eckstrom E
    Ann Intern Med; 2013 Nov; 159(9):601-12. PubMed ID: 24145578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.